Terns Pharmaceuticals, Inc.
$52.74
▼
-0.13%
2026-04-21 09:47:00
www.ternspharma.com
NMS: TERN
Explore Terns Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.09 B
Current Price
$52.74
52W High / Low
$53.19 / $2.23
Stock P/E
—
Book Value
$8.96
Dividend Yield
—
ROCE
-10.92%
ROE
-14.23%
Face Value
—
EPS
$-1.03
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
59
Beta
-0.38
Debt / Equity
0.09
Current Ratio
62.41
Quick Ratio
62.41
Forward P/E
-33.86
Price / Sales
—
Enterprise Value
$5.06 B
EV / EBITDA
-45.95
EV / Revenue
—
Rating
Hold
Target Price
$53.62
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Annexon, Inc. | $6.43 | — | $1.05 B | — | -92.11% | -81.9% | $7.18 / $1.4 | $1.42 |
| 2. | Kymera Therapeutics, Inc. | $88.84 | — | $7.31 B | — | -20.82% | -25.78% | $103 / $24.43 | $19.42 |
| 3. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 4. | Innoviva, Inc. | $23.92 | 6.53 | $1.77 B | — | 10.33% | 29.09% | $25.14 / $16.52 | $15.71 |
| 5. | 60 Degrees Pharmaceuticals, Inc. | $1.84 | — | $4.69 M | — | -220.2% | -2.01% | $17.68 / $1.29 | $-5.25 |
| 6. | EyePoint, Inc. | $15.07 | — | $1.26 B | — | -74.45% | -72.19% | $19.11 / $5.3 | $3.7 |
| 7. | Enanta Pharmaceuticals, Inc. | $13.78 | — | $409.17 M | — | -36.76% | -60.01% | $17.15 / $4.83 | $4.36 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -27.6 M | -27.72 M | -27.38 M | -27.43 M | -25.95 M | — |
| Net Profit | -23.57 M | -24.64 M | -24.09 M | -23.91 M | -21.8 M | — |
| EPS in Rs | -0.2 | -0.21 | -0.21 | -0.21 | -0.19 | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -110.12 M | -101.87 M | -102.56 M | -62.03 M |
| Net Profit | -96.21 M | -88.85 M | -90.21 M | -60.34 M |
| EPS in Rs | -0.83 | -0.77 | -0.78 | -0.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.03 B | 363.93 M | 268.52 M | 287.03 M |
| Total Liabilities | 18.55 M | 18.06 M | 13.15 M | 10.08 M |
| Equity | 1.01 B | 345.87 M | 255.37 M | 276.94 M |
| Current Assets | 1.02 B | 362.11 M | 267.43 M | 285.19 M |
| Current Liabilities | 16.41 M | 15.65 M | 11.94 M | 8.47 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -82.18 M | -70.02 M | -67.39 M | -49.11 M |
| Investing CF | -298.04 M | -12.41 M | -37.99 M | -22.27 M |
| Financing CF | 743.51 M | 164 M | 41.95 M | 167.09 M |
| Free CF | -82.18 M | -70.06 M | -67.44 M | -49.38 M |
| Capex | — | -0.04 M | -0.05 M | -0.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 1.5% | -49.49% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.